抗TNF药物治疗IBD孕妇的PBPK建模:预测妊娠停药与婴儿接种时机
本研究建立抗TNF药物(英夫利西单抗、阿达木单抗、戈利木单抗)的生理药代动力学(PBPK)模型,外推至孕妇、胎儿和婴儿。模型预测与观察数据在2倍范围内相符,据此给出妊娠期末次给药时机及婴儿出生后12、8、5个月接种疫苗的建议。
要点
- PBPK模型可预测抗TNF药物在孕妇、胎儿和婴儿中的药代动力学。
- 英夫利西单抗、阿达木单抗、戈利木单抗的婴儿推荐接种时机分别为出生后12、8、5个月。
- 模型预测药代动力学数据在观察数据2倍范围内。
核心结论
- PBPK模型可为孕妇、胎儿和婴儿中大分子药物的药代动力学预测提供有价值工具,辅助妊娠期用药决策和婴儿接种方案制定。
研究设计与样本
- 建立抗TNF药物(英夫利西单抗、阿达木单抗、戈利木单抗)的PBPK模型,从成人外推至孕妇、胎儿和婴儿。
主要发现
- PBPK模型成功预测并验证了英夫利西单抗、阿达木单抗和戈利木单抗在妊娠期、胎儿和婴儿中的药代动力学,预测数据在观察数据2倍范围内。
- 根据给药剂量,基于PBPK预测成功提供了英夫利西单抗、阿达木单抗和戈利木单抗的妊娠期末次给药时机建议。
- PBPK模型提示婴儿接种疫苗的推荐时机为出生后12个月(英夫利西单抗)、8个月(阿达木单抗)和5个月(戈利木单抗)。
临床怎么用
- 可利用PBPK模型预测的妊娠期末次给药时机指导IBD孕妇抗TNF药物的停药决策。
- 可参考PBPK模型预测的月龄安排抗TNF药物暴露婴儿的疫苗接种时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-tumor necrosis factor (anti-TNF) agents are widely applied for patients with inflammatory bowel disease (IBD); however, the timing of the last dosing for IBD pregnancy and time to elimination in anti-TNF agent-exposed infants is controversial. This study aimed to determine the optimal timing for the last dosing of anti-TNF agents (infliximab, adalimumab, and golimumab) in pregnant women with IBD, as well as to investigate the recommended vaccine schedules for infants exposed to these drugs. A physiologically-based pharmacokinetic (PBPK) model of anti-TNF agents was built for adults and extrapolated to pregnant patients, fetuses, and infants. The PBPK models successfully predicted and verified the pharmacokinetics (PKs) of infliximab, adalimumab, and golimumab in pregnancy, fetuses, and infants. The predicted PK data were within two-fold of the observed data. The simulated results were used as timing advice. According to the dose of administration, the suggested timing of the last dosing for infliximab, adalimumab, and golimumab is successfully provided based on PBPK predictions. PBPK models indicated that, for infants, the advocated timing of vaccination is 12, 8, and 5 months after birth for infliximab, adalimumab, and golimumab, respectively. Our study illustrated that PBPK models can provide a valuable tool to predict the PKs of large macromolecules in pregnant women, fetuses, and infants, ultimately informing drug-treatment decisions for pregnancy and vaccination regimens for infants.
引用
- Chen J, Lin R, Guo G, et al. Physiologically-Based Pharmacokinetic Modeling of Anti-Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Patients to Predict the Withdrawal Time in Pregnancy and Vaccine Time in Infants. Clin Pharmacol Ther. 2023. PMID: 37620249. doi:10.1002/cpt.3031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。